nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg qikanlogo popupnotification paper
2024 06 v.40 1411-1419
细胞来源培养的流感疫苗研究进展
基金项目(Foundation): 中国医学科学院医学与健康科技创新工程,重大协同创新项目(项目号:2021-I2M-1-043),题目:创新疫苗关键技术研究~~
邮箱(Email): lwd@imbcams.com.cn;
DOI: 10.13242/j.cnki.bingduxuebao.004574
中文作者单位:

中国医学科学院北京协和医学院医学生物学研究所云南省重大传染病疫苗研发重点实验室;

摘要(Abstract):

流感是由流感病毒引起的急性呼吸道传染病,接种相应的流感疫苗是预防和控制流感传播及流感导致的严重并发症的最经济有效的手段,由于基于鸡胚培养的流感疫苗在面临大流行威胁时可能存在鸡胚无法及时供应、难以快速大规模的生产疫苗等不足,细胞来源培养的流感疫苗的开发与生产越来越受到重视。本文主要从目前开发的用于生产流感疫苗的几种生产细胞(MDCK、Vero、PER.C6和昆虫细胞)的临床前和临床研究进展、优缺点以及不同细胞培养的流感病毒的工艺及细胞基质流感疫苗的质量控制等方面进行综述。

关键词(KeyWords): 细胞来源;流感疫苗;PER.C6;MDCK;Vero;昆虫细胞
参考文献 [1] Lu B, Zhou H, Ye D, et al. Improvement of influenza A/Fujian/411/02(H3N2)virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics[J]. J Virol, 2005, 79(11):6763-6771. DOI:10. 1128/jvi. 79. 11. 6763-6771. 2005.
[2] Widjaja L, Ilyushina N, Webster RG, et al. Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs[J]. Virology, 2006,350(1):137-145. DOI:10. 1016/j.virol. 2006. 02. 020.
[3] Yang D, Huang L, Wang J, et al. Tumorigenesis mechanism and application strategy of the MDCK cell line:a systematic review[J]. Biologicals, 2023, 83:101699. DOI:10. 1016/j. biologicals. 2023. 101699.
[4] Haredy AM, Takenaka N, Yamada H, et al. An MDCK cell culture-derived formalin-inactivated influenza virus whole-virion vaccine from an influenza virus library confers cross-protective immunity by intranasal administration in mice[J]. Clin Vaccine Immunol, 2013, 20(7):998-1007. DOI:10. 1128/cvi. 00024-13.
[5] Chia MY, Hu AY, Tseng YF, et al. Evaluation of MDCK cell-derived influenza H7N9 vaccine candidates in ferrets[J]. PLoS One, 2015, 10(3):e0120793.DOI:10. 1371/journal. pone. 0120793.
[6] Moro PL, Winiecki S, Lewis P, et al. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture(Flucelvax?)reported to the Vaccine Adverse Event Reporting System(VAERS), United States, 2013–2015[J]. Vaccine, 2015, 33(48):6684-6688. DOI:10. 1016/j. vaccine. 2015. 10. 084.
[7] Manini I, Trombetta CM, Lazzeri G, et al. Eggindependent influenza vaccines and vaccine candidates[J]. Vaccines(Basel), 2017, 5(3):E18. DOI:10. 3390/vaccines5030018.
[8] Manini I, Domnich A, Amicizia D, et al. Flucelvax(Optaflu)for seasonal influenza[J]. Expert Rev Vaccines, 2015, 14(6):789-804. DOI:10. 1586/14760584. 2015. 1039520.
[9] Lamb YN. Cell-based quadrivalent inactivated influenza virus vaccine(flucelvax?Tetra/flucelvax quadrivalent?):a review in the prevention of influenza[J]. Drugs, 2019, 79(12):1337-1348. DOI:10. 1007/s40265-019-01176-z.
[10]Kulkarni PS, Agarkhedkar S, Lalwani S, et al.Effectiveness of an Indian-made attenuated influenza a(H1N1)pdm 2009 vaccine:a case control study[J].Hum Vaccin Immunother, 2014, 10(3):566-571.DOI:10. 4161/hv. 27490.
[11]Cox MMJ, Hashimoto Y. A fast track influenza virus vaccine produced in insect cells[J]. J Invertebr Pathol,2011, 107:S31-S41. DOI:10. 1016/j.jip. 2011. 05. 003.
[12]Choi WS, Noh JY, Song JY, et al. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine(NBP607-QIV):a randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects[J]. Hum Vaccin Immunother, 2017, 13(7):1653-1660. DOI:10. 1080/21645515. 2017. 1297351.
[13]Song JY, Cheong HJ, Lee J, et al. Immunogenicity and safety of a cell culture-derived inactivated trivalent influenza vaccine(NBP607):a randomized, doubleblind, multi-center, phase 3 clinical trial[J]. Vaccine,2015, 33(41):5437-5444. DOI:10. 1016/j.vaccine. 2015. 08. 030.
[14]Montomoli E, Khadang B, Piccirella S, et al. Cell culture-derived influenza vaccines from Vero cells:a new horizon for vaccine production[J]. Expert Rev Vaccines, 2012, 11(5):587-594. DOI:10. 1586/erv. 12. 24.
[15]Barr IG, Donis RO, Katz JM, et al. Cell culturederived influenza vaccines in the severe 2017–2018epidemic season:a step towards improved influenza vaccine effectiveness[J]. NPJ Vaccines, 2018, 3:44.DOI:10. 1038/s41541-018-0079-z.
[16]de Vries RP, de Vries E, Bosch BJ, et al. The influenza A virus hemagglutinin glycosylation state affects receptor-binding specificity[J]. Virology, 2010,403(1):17-25. DOI:10. 1016/j. virol. 2010. 03. 047.
[17]Chan CY, Tambyah PA. Preflucel?:a Vero-cell culture-derived trivalent influenza vaccine[J]. Expert Rev Vaccines, 2012, 11(7):759-773. DOI:10. 1586/erv. 12. 55.
[18]Grohskopf LA, Blanton LH, Ferdinands JM, et al.Prevention and control of seasonal influenza with vaccines:recommendations of the advisory committee on immunization practices-United States, 2022-23influenza season[J]. MMWR Recomm Rep, 2022, 71(1):1-28. DOI:10. 15585/mmwr. rr7101a1.
[19]国家药品监督管理局药品审评中心[EB/OL]. 2024-06-29[2024-06-29]. https://www. cde. org. cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c
[20]Ugiyadi M, Tan MI, Giri-Rachman EA, et al. The expression of essential components for human influenza virus internalisation in Vero and MDCK cells[J].Cytotechnology, 2014, 66(3):515-523. DOI:10. 1007/s10616-013-9602-2.
[21]Shin D, Park KJ, Lee H, et al. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines[J]. Virus Res, 2015, 204:40-46. DOI:10. 1016/j. virusres. 2015. 04. 005.
[22]Boikos C, McGovern I, Molrine D, et al. Review of analyses estimating relative vaccine effectiveness of cellbased quadrivalent influenza vaccine in three consecutive US influenza seasons[J]. Vaccines(Basel), 2022, 10(6):896. DOI:10. 3390/vaccines10060896.
[23]Divino V, Krishnarajah G, Pelton SI, et al. A realworld study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017–18 influenza season[J]. Vaccine,2020, 38(40):6334-6343. DOI:10. 1016/j.vaccine. 2020. 07. 023.
[24]Zhang J, Nian X, Liu B, et al. Development of MDCKbased quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection:a preclinical study[J]. Antivir Res, 2023, 216:105639. DOI:10. 1016/j. antiviral. 2023. 105639.
[25]Onions D, Egan W, Jarrett R, et al. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine[J]. Biologicals, 2010,38(5):544-551. DOI:10. 1016/j.biologicals. 2010. 04. 003.
[26]Ma GL, Qiao ZL, He D, et al. Establishment of a lowtumorigenic MDCK cell line and study of differential molecular networks[J]. Biologicals, 2020, 68:112-121. DOI:10. 1016/j. biologicals. 2020. 07. 003.
[27]Vepachedu RS, Menon A, Hussain AI, et al.Evaluation of tumorigenic potential of high yielding cloned MDCK cells for live-attenuated influenza vaccine using in vitro growth characteristics, metastatic gene expression and in vivo nude mice model[J].Biologicals, 2012, 40(6):482-494. DOI:10. 1016/j.biologicals. 2012. 06. 005.
[28]Tseng YF, Hu AY, Huang ML, et al. Adaptation of high-growth influenza H5N1 vaccine virus in Vero cells:implications for pandemic preparedness[J]. PLoS One,2011, 6(10):e24057. DOI:10. 1371/journal.pone. 0024057.
[29]Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu(Novartis Vaccines)[J]. Expert Rev Vaccines, 2009, 8(6):679-688. DOI:10. 1586/erv. 09. 31.
[30]van der Velden MV, Aichinger G, P?llabauer EM, et al. Cell culture(Vero cell)derived whole-virus nonadjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response:homologous or heterologous booster response following two dose or single dose priming[J]. Vaccine, 2012, 30(43):6127-6135. DOI:10. 1016/j. vaccine. 2012. 07. 077.
[31]van der Velden MV, Geisberger A, Dvorak T, et al.Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients[J]. Clin Vaccine Immunol, 2014, 21(6):867-876. DOI:10. 1128/cvi. 00065-14.
[32]Romanova J, Katinger D, Ferko B, et al. Distinct host range of influenza h3n2 virus isolates in vero and mdck cells is determined by cell specific glycosylation pattern[J]. Virology, 2003, 307(1):90-97. DOI:10. 1016/S0042-6822(02)00064-8.
[33]Brühl P, Kerschbaum A, Kistner O, et al. Humoral and cell-mediated immunity to Vero cell-derived influenza vaccine[J]. Vaccine, 2000, 19(9-10):1149-1158. DOI:10. 1016/S0264-410X(00)00316-9.
[34]Kaverin NV, Webster RG. Impairment of multicycle influenza virus growth in Vero(WHO)cells by loss of trypsin activity[J]. J Virol, 1995, 69(4):2700-2703.DOI:10. 1128/jvi. 69. 4. 2700-2703. 1995.
[35]Fallaux FJ, Bout A, van der Velde I, et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses[J]. Hum Gene Ther, 1998, 9(13):1909-1917. DOI:10. 1089/hum. 1998. 9. 13-1909.
[36]Lewis JA, Brown EL, Duncan PA. Approaches to the release of a master cell bank of PER. C6 cells; a novel cell substrate for the manufacture of human vaccines[J].Dev Biol(Basel), 2006, 123:165-76;discussion183-97.
[37] PauMG, OphorstC, KoldijkMH, et al. The human cell line PER. C6 provides a new manufacturing system for the production of influenza vaccines[J].Vaccine, 2001, 19(17-19):2716-2721. DOI:10. 1016/S0264-410X(00)00508-9.
[38]Koudstaal W, Hartgroves L, Havenga M, et al.Suitability of PER. C6?cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics[J]. Vaccine, 2009, 27(19):2588-2593. DOI:10. 1016/j. vaccine. 2009. 02. 033.
[39]Cox RJ, Madhun AS, Hauge S, et al. A phase I clinical trial of a PER. C6?cell grown influenza H7 virus vaccine[J]. Vaccine, 2009, 27(13):1889-1897. DOI:10. 1016/j. vaccine. 2009. 01. 116.
[40]Ledwith BJ, Lanning CL, Gumprecht LA, et al.Tumorigenicity assessments of Per. C6 cells and of an Ad5-vectored HIV-1 vaccine produced on this continuous cell line[J]. Dev Biol, 2006, 123:251-63;discussion265.
[41]Hong M, Li T, Xue W, et al. Genetic engineering of baculovirus-insect cell system to improve protein production[J]. Front Bioeng Biotechnol, 2022, 10:994743. DOI:10. 3389/fbioe. 2022. 994743.
[42]Dunkle LM, Izikson R, Patriarca P, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older[J]. N Engl J Med, 2017, 376(25):2427-2436.DOI:10. 1056/nejmoa1608862.
[43]Hu J, Zhang Q, Peng P, et al. Baculovirus-derived influenza virus-like particle confers complete protection against lethal H7N9 avian influenza virus challenge in chickens and mice[J]. Vet Microbiol, 2022, 264:109306. DOI:10. 1016/j. vetmic. 2021. 109306.
[44]Silvano M, Correia R, Virgolini N, et al. Gene expression analysis of adapted insect cells during influenza VLP production using RNA-sequencing[J].Viruses, 2022, 14(10):2238. DOI:10. 3390/v14102238.
[45]Wagner R, Geyer H, Geyer R, et al. N-acetyl-betaglucosaminidase accounts for differences in glycosylation of influenza virus hemagglutinin expressed in insect cells from a baculovirus vector[J]. J Virol, 1996, 70(6):4103-4109. DOI:10. 1128/jvi. 70. 6. 4103-4109. 1996.
[46]Buckland B, Boulanger R, Fino M, et al. Technology transfer and scale-up of the Flublok?recombinant hemagglutinin(HA)influenza vaccine manufacturing process[J]. Vaccine, 2014, 32(42):5496-5502. DOI:10. 1016/j. vaccine. 2014. 07. 074.
[47]Wang WC, Sayedahmed EE, Sambhara S, et al.Progress towards the development of a universal influenza vaccine[J]. Viruses, 2022, 14(8):1684.DOI:10. 3390/v14081684.
[48]Kamal RP, Blanchfield K, Belser JA, et al. Inactivated H7 influenza virus vaccines protect mice despite inducing only low levels of neutralizing antibodies[J]. J Virol,2017, 91(20):e01202-e01217. DOI:10. 1128/jvi. 01202-17.
[49]B Carvalho S, Peixoto C, T Carrondo MJ, et al.Downstream processing for influenza vaccines and candidates:an update[J]. Biotechnol Bioeng, 2021,118(8):2845-2869. DOI:10. 1002/bit. 27803.
[50]Gregersen JP, Schmitt HJ, Trusheim H, et al. Safety of MDCK cell culture-based influenza vaccines[J].Future Microbiol, 2011, 6(2):143-152. DOI:10. 2217/fmb. 10. 161.
[51]Magini D, Giovani C, Mangiavacchi S, et al. Selfamplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge[J].PLoS One, 2016, 11(8):e0161193. DOI:10. 1371/journal. pone. 0161193.
[52]杨晓明. 2011年欧洲药典和英国药典选编(生物制品)[M].中国生物技术集团公司:湖北省内部图书准印证,2011.
[53]FDA. Guidance for industry:characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications[S]. 2010:5-16(2010-02)[2024-06-30]. https://www. fda. gov/regulatoryinformation/search-fda-guidance-documents/characteriza tion-and-qualification-cell-substrates-and-other-biological-materials-used-production.

基本信息:

DOI:10.13242/j.cnki.bingduxuebao.004574

中图分类号:R392

引用信息:

[1]李双丽,吴雅楠,吴雯西等.细胞来源培养的流感疫苗研究进展[J].病毒学报,2024,40(06):1411-1419.DOI:10.13242/j.cnki.bingduxuebao.004574.

基金信息:

中国医学科学院医学与健康科技创新工程,重大协同创新项目(项目号:2021-I2M-1-043),题目:创新疫苗关键技术研究~~

检 索 高级检索

引用

GB/T 7714-2015 格式引文
MLA格式引文
APA格式引文